Journal article

Cost‐Effectiveness of Combination Therapy for Patients With Systemic Sclerosis–Related Pulmonary Arterial Hypertension

An Tran‐Duy, Kathleen Morrisroe, Philip Clarke, Wendy Stevens, Susanna Proudman, Joanne Sahhar, Mandana Nikpour

Journal of the American Heart Association | Ovid Technologies (Wolters Kluwer Health) | Published : 2021


Background: To evaluate the cost‐effectiveness of combination pulmonary arterial hypertension specific therapy in systemic sclerosis–related PAH. Methods and Results: Health outcomes and costs were captured through data linkage. Health utility was derived from Medical Outcomes Study Short Form‐36 scores. A probabilistic discrete‐time model was developed to simulate lifetime changes in costs and health utility. Mortality was predicted using a Gompertz parametric survival model. For both treatment arms, the simulations were started using the same cohort of 10 000 patients. Probabilistic sensitivity analysis was performed using the Monte Carlo simulation with 1000 sets of sampled parameter val..

View full abstract


Awarded by National Health and Medical Research Council of Australia Investigator Grant

Funding Acknowledgements

This work was supported by Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia, and Pfizer. MN holds a National Health and Medical Research Council of Australia Investigator Grant (GNT1176538). KM holds a Royal Australasian College of Physicians (RACP), Australian Rheumatology Association (ARA), and DEV Starr Research Establishment Fellowship. AT-D is partly supported by Australian Research Council Centre of Excellence in Population Ageing Research.